AI in Life Science Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Deployment, By Application, By Region & Competition, 2021-2031F

The global market for AI in Life Science is projected to expand significantly, increasing from USD 14.21 billion in 2025 to USD 33.61 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 15.43%. This sector integrates artificial intelligence technologies, including machine learning, natural language processing, and advanced computational algorithms, to expedite drug discovery, refine clinical trial methodologies, and improve diagnostic precision.

The market's growth is largely fueled by the surging volume of intricate biomedical data, which demands automated analytical solutions for effective processing, alongside the critical need to mitigate the high costs and protracted timelines inherent in pharmaceutical development. However, a notable challenge persists in the form of a shortage of technical experts, impeding the seamless integration and scaling of AI solutions. Businesses struggle to find professionals skilled in both biological sciences and data engineering, with the Pistoia Alliance reporting in 2025 that 34% of industry participants identified a lack of skilled personnel as a primary obstacle to AI adoption in laboratory settings, consequently limiting the full potential of computational tools and overall market expansion.

Market Driver

A fundamental driver for market growth is the pressing need to accelerate drug discovery and reduce substantial research and development expenses, aiming to move beyond the conventional, capital-intensive pharmaceutical paradigm. AI algorithms are increasingly utilized to forecast molecular interactions and refine lead candidates, significantly cutting down the multi-year preclinical testing phases. This enhanced efficiency is attracting substantial financial investments from leading pharmaceutical firms looking to incorporate validated AI platforms into their development processes, exemplified by AstraZeneca's partnership with CSPC Pharmaceuticals, which included a $110 million upfront payment and up to $3.6 billion in potential milestone payments, as reported by Labiotech.eu in October 2025.

Simultaneously, swift progress in generative AI and deep learning models is transforming the technological foundation of the life sciences industry. These models' capacity to analyze extensive multi-omics datasets and engineer novel protein structures has generated considerable demand for advanced computing power. This trend is reflected in the rapid expansion of technology providers; for instance, NVIDIA's Data Center revenue surged to a record $51.2 billion in November 2025, a 66% increase largely attributable to the deployment of foundation models for biological and industrial uses, as detailed in their Q3 Fiscal 2026 report. Such technological maturity is also drawing significant venture capital into specialized companies, with Isomorphic Labs securing $600 million to advance its AI-driven drug design, underscoring the market's conviction in deep learning's potential for therapeutic innovations, according to Tech Funding News in December 2025.

Market Challenge

The shortage of specialized technical expertise significantly impedes the growth of the Global AI in Life Science Market, primarily by hindering the progression from pilot projects to comprehensive commercial implementation. This challenge arises from the need for professionals with a "bilingual" skillset, meaning individuals must possess both profound knowledge in intricate biological sciences and advanced competency in data engineering. Without this combined capability, organizations encounter operational obstacles, preventing the effective validation of computational insights or their translation into actionable R&D results, thereby causing substantial delays in product development.

This dearth of skilled personnel compels companies to reallocate resources towards internal training and upskilling initiatives, rather than focusing on immediate market expansion. The extent of this internal knowledge gap is considerable; the Pistoia Alliance reported in 2025 that 45% of industry professionals specifically sought educational courses in AI and machine learning to address their skill deficiencies. This strong demand for fundamental training suggests that a significant segment of the current workforce is not yet equipped to utilize advanced AI tools. As a result, the market's growth momentum is slowed, as businesses must first establish essential human capital before they can fully exploit automated analytical capabilities.

Market Trends

A significant trend involves the increasing adoption of autonomous AI agents for streamlining complex workflow automation, marking a shift from static, prompt-driven tools to self-governing systems capable of fulfilling multi-step objectives. These agents operate independently, managing regulatory compliance, validating scientific data, and producing submission-ready documentation without continuous human intervention, thereby substantially alleviating administrative bottlenecks. This functionality is crucial for minimizing the manual effort typically associated with compliance and clinical reporting, as evidenced by Deep Intelligent Pharma's May 2025 press release, which highlighted their platform's ability to reduce clinical and regulatory documentation time by over 90% using multi-agent AI swarms for automated statistical reasoning and validation.

Simultaneously, the application of generative AI for de novo protein and antibody design is transforming the sector from merely screening existing libraries to actively engineering novel biological entities possessing specific therapeutic characteristics. Utilizing foundation models trained on extensive biological datasets, researchers can now design proteins from the ground up, optimizing them for developability and binding affinity even before physical synthesis. This shift from pure discovery to an engineering-driven approach is attracting considerable investment, confirming the commercial potential of generative biology. For example, Chai Discovery secured a $130 million Series B funding round to advance these generative capabilities and redefine molecular biology as an engineering discipline, according to a December 2025 US Tech Times article.

Key Market Players

• IBM Corporation
• Atomwise Inc.
• Nuance Communications, Inc.
• NuMedii, Inc.
• AiCure LLC
• Apixio Holdings, LLC
• Insilico Medicine
• Enlitic, Inc.
• Sensely, Inc.
• SINEQUA Group

Report Scope

In this report, the Global AI in Life Science Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI in Life Science Market, By Offering

• Software
• Hardware
• Services

AI in Life Science Market, By Deployment

• On-Premises
• Cloud

AI in Life Science Market, By Application

• Medical Diagnosis
• Drug Discovery
• Precision & Personalized Medicine
• Biotechnology
• Clinical Trials
• Patent Monitoring

AI in Life Science Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in Life Science Market.

Available Customizations:

Global AI in Life Science Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).